Fouad Albana
Nephrology · Holmdel, NJNPI 1750326211
Payments from drug & device makers
Across 154 payments — averaging $36.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$3K
- AstraZeneca$505
- Bayer$356
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$329
- Merck$216
- Otsuka America Pharmaceutical, Inc.$214
- plus $879 from 17 others
What the payments were for
- Food & beverage$2,42643%
- Education$1372%
- Other$3,07055%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson(3 entities) | 5 | $3,134 |
| AstraZeneca | 28 | $505 |
| Bayer | 16 | $356 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 24 | $329 |
| Merck | 15 | $216 |
| Otsuka America Pharmaceutical, Inc. | 9 | $214 |
| Amgen(2 entities) | 9 | $134 |
| Mallinckrodt Hospital Products Inc. | 8 | $107 |
| Indivior Inc. | 7 | $105 |
| OPKO Pharmaceuticals, LLC | 7 | $100 |
| Novartis | 4 | $84 |
| Novo Nordisk | 4 | $75 |
| Avanir Pharmaceuticals, Inc. | 4 | $55 |
| Ascensia Diabetes Care US Inc. | 3 | $42 |
| Abbott | 2 | $39 |
| Lilly USA, LLC | 2 | $33 |
| Vifor Pharma, Inc. | 1 | $19 |
| Daiichi Sankyo Inc. | 1 | $15 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $15 |
| E.r. Squibb & Sons, L.L.C. | 1 | $15 |
| Alfasigma USA, Inc. | 1 | $15 |
| Ultragenyx Pharmaceutical Inc. | 1 | $14 |
| Fresenius USA Marketing, Inc. | 1 | $14 |
How this compares
$5,633 in reported general payments places this provider in the 80th percentile of 413 nephrology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 216 | $84,063 |
| OzempicSemaglutide | 54 | $55,910 |
| FarxigaDapagliflozin Propanediol | 55 | $43,311 |
| XareltoRivaroxaban | 128 | $38,425 |
| JanuviaSitagliptin Phosphate | 58 | $36,437 |
| JardianceEmpagliflozin | 76 | $35,817 |
| KerendiaFinerenone | 22 | $35,322 |
| FetrojaCefiderocol Sulfate Tosylate | 11 | $20,019 |
| BrilintaTicagrelor | 73 | $17,048 |
| EntrestoSacubitril/Valsartan | 46 | $15,890 |
| SantylCollagenase Clostridium Hist. | 26 | $11,635 |
| TrulicityDulaglutide | 11 | $10,832 |
| TradjentaLinagliptin | 33 | $9,008 |
| Atorvastatin Calcium | 373 | $5,564 |
| Potassium Chloride | 214 | $5,012 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Brilinta | $505 | $60,359128 claims |
| Novo NordiskOzempic, Fiasp | $75 | $59,36565 claims |
| Johnson & JohnsonXarelto | $3,134 | $38,425128 claims |
| MerckJanuvia | $216 | $36,43758 claims |
| BayerKerendia | $356 | $35,32222 claims |
| NovartisEntresto | $84 | $15,89046 claims |
| Lilly USA, LLCTrulicity | $33 | $10,83211 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 413 nephrology providers in New Jersey.
Other nephrology in Holmdel
- Danny HaddadJersey City$1.7M
- Anup PatelWest Orange$1M
- Joshua KaplanNewark$509K
- Lawrence ByrdLivingston$338K
- Devang LodhaviaVoorhees$321K
- Jeffrey FeldmanUnion$315K
- Kenneth LissEatontown$271K
- Narender GoelJersey City$181K
- Vadim FinkielsteinPrinceton Junction$139K
- Neeraj SinghNew Brunswick$133K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.